EXTON, Pa., May 31 /PRNewswire-FirstCall/ -- Kensey Nash Corporation is scheduled to present at the Pacific Growth Equities Life Sciences Growth Conference at the InterContinental Mark Hopkins Hotel in San Francisco, California on Tuesday, June 13, 2006.
Wendy F. DiCicco, Kensey Nash’s CFO, will deliver the Company’s presentation, beginning at approximately 8:30 a.m. (PT). The presentation materials will be available on the company’s website (http://www.kenseynash.com) beginning at 8:30 a.m. (PT) on Tuesday, June 13, 2006 and will remain on the website for approximately two weeks. Thomson will be web-casting the presentation, which can be accessed via the company’s website (http://www.kenseynash.com).
About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. The Company has created an Endovascular division, with a direct sales force in the U.S. and Germany. Endovascular products include devices for Embolic Protection and Thrombectomy applications. Our Biomaterial products used primarily in sports medicine, spine, and cardiology are commercialized through numerous corporate partners/customers. Kensey Nash is also known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Cautionary Note Regarding Forward-Looking Statements. This press release contains forward-looking statements that reflect Kensey Nash’s current expectations about its prospects and opportunities, including, without limitation, expectations regarding Kensey Nash’s TriActiv(R) System and its other endovascular products. Kensey Nash has tried to identify these forward- looking statements by using words such as “plans,” “believes,” “expects,” “anticipates,” “will,” “should” or similar expressions, but these words are not the exclusive means for identifying such statements. Kensey Nash cautions that a number of risks, uncertainties, and other important factors could cause Kensey Nash’s actual results, performance or achievements to differ materially from those expressed in, or implied by, these forward-looking statements, including, without limitation, the ability of Kensey Nash to obtain necessary regulatory approvals for other versions of the TriActiv(R) System and other new endovascular products, the ability of Kensey Nash to successfully market the TriActiv(R) System and other endovascular products, and competition from other technologies in the embolic protection market. For a more detailed discussion of these and other factors, please see Kensey Nash’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, Kensey Nash undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Kensey Nash Corporation
CONTACT: Joseph W. Kaufmann, President and Chief Executive Officer, KenseyNash Corporation, +1-484-713-2100
Web site: http://www.kenseynash.com/
